Male Vitality Supplement Guide: What The Evidence Shows

The aisle sells four things in different proportions: drive, stamina, physical performance and a general sense of vitality. Those are structure-function claims, which is the only category of claim a dietary supplement may make in the United States without being regulated as a drug.

What they may not claim is treatment, and the distinction matters more here than in most aisles. Erectile dysfunction is a medical diagnosis with medical causes, and MedlinePlus sets out the vascular, neurological, hormonal and medication-related ones. A supplement addresses none of them.

It is also worth knowing how much of the outcome sits outside any bottle. a meta-analysis of 89 population studies pooled 89 population studies and found sleep, body weight, smoking, alcohol intake and physical activity all associated with sexual function, several more strongly than any supplement trial here has reported. That is the context every supplement trial runs inside.

Ginseng is the strongest evidence in the aisle and the strength is still modest. the 2021 Cochrane review pooled nine trials in 587 men and reported a benefit on erectile function scores, while rating the certainty of that evidence as low and noting that the included studies were small and often poorly reported. That is a positive result described honestly by the people who ran the analysis.

a meta-analysis of 24 herbal trials pooled 24 randomised trials of herbal preparations from a wider base and found ginseng among the few with a measurable signal, while a review of 65 randomised trials of the root read 65 randomised trials of the root and called that literature promising but methodologically uneven.

Four trials, four preparations, and not one of them below a gram a day except the performance study, which found the larger dose worked and the smaller one did not.

The table is the reason dose matters more in this aisle than brand does. the Sao Paulo trial at 3,000 mg a day ran at three grams of Korean red ginseng a day. a 143-man trial at 2,000 mg a day ran at two grams of a tissue-cultured extract in 143 men. the ginseng berry study at 1,400 mg a day ran at 1.4 grams of berry extract. A capsule holding a few hundred milligrams of a six-ingredient blend is not in the same conversation as any of those figures, whatever the front of the box says.

One finding belongs here because it is routinely misquoted. the one hormone trial at 3 g a day gave three grams a day to men with metabolic syndrome and measured hormones directly. Testosterone did not change.

Maca is the cleanest dose signal in the aisle, and the reason is a single well-built study. the dose-finding study where 1.5 g did nothing and 3 g did was a double-blind dose-finding trial that ran two arms at once: 1,500 mg a day and 3,000 mg a day. The higher arm produced a measurable improvement and the lower arm did not. One study, two doses, one answer, and it is the kind of result the rest of this category almost never produces.

the 12-week desire trial had already reported improved sexual desire over twelve weeks in healthy men at 1,500 and 3,000 mg a day, and its companion paper the companion hormone paper measured the reproductive hormones in the same men and found them unchanged. Whatever maca is doing, it is not doing it through testosterone.

the systematic review of four trials pooled four randomised trials and called the evidence limited but suggestive, and a 175-person trial of the spray-dried extract tested black and red maca extracts in 175 people at altitude with acceptable safety and modest effects.

Tribulus terrestris is the botanical this aisle sells hardest on a hormonal story, and it is the one where that story has been tested most often and failed most consistently. the androgen study that found nothing gave it to young men and measured androgen production directly. Nothing moved. the rugby trial at 450 mg a day ran 450 mg a day for five weeks in elite rugby league players during preseason and found no change in strength or body composition. an eight-week resistance-training trial ran an eight-week trial in resistance-trained men and reported the same nothing.

Three research groups, two populations, one consistent negative. the review of 27 marketed testosterone boosters put that in context by reviewing 27 marketed testosterone boosters and finding most of them had no human evidence behind the claim on the box.

The erectile-function literature is kinder and still thin. a 2026 meta-analysis of eight trials pooled eight randomised trials and reported a small improvement in symptom scores, a placebo-controlled study in men with late-onset hypogonadism ran a placebo-controlled study in men with late-onset hypogonadism, the 2025 review that collected the doses found the clinical doses cluster between 400 and 750 mg a day, and a review that ranked the botanicals against each other set tribulus beside the rest of the class and found all of it weak.

Epimedium, sold as horny goat weed, has the most seductive mechanism in the aisle and almost no human outcome data behind it. Its flavonoid icariin inhibits phosphodiesterase-5, the enzyme the prescription drugs in this space act on. the enzyme study on icariin analogues explored icariin analogues and identified the structural features driving potent inhibition of the human enzyme, and a review of 97 plants screened for the same enzyme screened 97 plants against the same target.

The gap is what happened next, which is very little. a 2026 review of the mechanism work reviewed the mechanism work in 2026 and it remains largely laboratory work. the only modern randomised trial of a purified Epimedium extract is the modern randomised trial of a purified prenylflavonoid extract, at 740 mg a day in postmenopausal women with bone endpoints, and the 24-month bone trial at 60 mg of icariin a day ran 60 mg of icariin a day for 24 months in the same population.

So the two best human trials of this plant were in women, for a skeletal outcome, and neither was built to answer the question this aisle asks. Potency against an enzyme in a dish is a reason to run a trial rather than a trial result.

Honey turns up in this aisle for reasons that are partly cultural and partly commercial, and its research literature is about neither drive nor testosterone. the 2025 umbrella review is a 2025 umbrella review with a GRADE-assessed meta-analysis, and the dose it pools for cardiometabolic outcomes is around 10 grams a day.

The sports work uses larger amounts still. a 2025 cycling trial compared honey against a conventional carbohydrate sports product across three hours of steady-state cycling and found comparable metabolic responses, at the sort of intake a sports drink delivers. a soccer-simulation trial tested a honey-sweetened beverage against a soccer simulation.

Ten grams is ten thousand milligrams, and no capsule holds it. Honey in a capsule is a flavour, a binder and a brand signature rather than an active dose of anything.

Two short safety notes. the global review of infant botulism reviews the global epidemiology of infant botulism and honey exposure, which is why honey stays away from children under one, and a 2026 pharmacovigilance overview of bee products is a 2026 pharmacovigilance overview of bee products worth a look by anybody with a pollen allergy.

Piperine is in these formulas to change absorption rather than to do anything on its own, and it genuinely does. the study that identified what piperine does to drug handling identified piperine as an inhibitor of both human P-glycoprotein and CYP3A4, the transporter and the enzyme that between them handle a large fraction of oral medicines.

The effect also runs the other way with repeated exposure. the paper showing the effect runs both ways showed piperine activating the pregnane X receptor, which induces CYP3A4 and multidrug resistance protein 1 rather than blocking them. a review of black pepper and drug absorption reviews what that means for intestinal absorption and hepatic metabolism of drugs, and a chapter on piperine's own pharmacology covers piperine's own pharmacology.

The practical reading applies to every formula in the aisle carrying this ingredient rather than to any one brand. If you take a prescription medicine, an absorption modifier is the row to raise with whoever prescribed it, because it can move the level of something else in either direction.

• Find the dose first. It is the most transferable fact in a paper, and a trial at 3,000 mg a day says nothing useful about a capsule holding a fraction of it.
• Check who was in it. Men with diagnosed erectile dysfunction, healthy young men, trained athletes and postmenopausal women are four populations, and results do not carry between them.
• Check what was measured. A symptom questionnaire, a blood hormone level and a performance test are three endpoints, and moving one is not moving the others.
• Check the length. Eight to twelve weeks is the norm here. A claim about the first week is not coming from a trial.
• Prefer a pooled analysis. One positive study is a hypothesis; a systematic review with its certainty rated is a finding.

Male vitality is the supplement category with the worst documented adulteration record. ten years of FDA adulteration warnings analysed ten years of FDA warnings about unapproved pharmaceutical ingredients in dietary supplements, and sexual-enhancement products are one of the three categories dominating that list.

a laboratory test of six products sold as 100% natural bought male enhancement products sold online as entirely natural and tested in a laboratory what the capsules actually contained. a commentary on the same problem is a commentary on the same problem, an analysis of the six best-selling online products analysed the most popular online products of this kind, a scoring study of 25 marketed blends scored 25 marketed blends against the doses their ingredients were studied at, and a 2026 meta-analysis of 14 herbal trials pooled 14 randomised trials and found a small effect across a weak literature.

Four things, and the first is the one most readers arrive without. Nothing in this aisle acts on the day. The trials that reported anything ran eight to twelve weeks, so a product is worth judging over a bottle or three rather than a weekend.

Second, read the panel rather than the front: the amount is the fact and the name is marketing. Third, compare a printed amount against the dose in this guide rather than against another brand's panel, because two products can be equally far short of the research and still look reasonable beside each other. Fourth, buy where a refund exists, because in a category with this adulteration record a long window with a telephone number behind it is worth more than any seal.

HoneyPower, the capsule sold here, meets the fourth rule and is candid about the first. It names 6 ingredients and gives an amount for none, so the second and third cannot be run on it at all. The scorecard works through that, and the ingredients page prints the trial dose beside each name.